Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 3,446 out of 355,674 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 113,263 | 124,018 |
| Total Cites | 2,010 | 2,134 |
| H-index | 21 | 22 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 17 | 17 |
| Total Cites to Single+First Authored Papers | 105 | 110 |
| Number of Single+First+Last Authored Papers | 24 | 24 |
| Total Cites to Single+First+Last Authored Papers | 208 | 216 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 1,689 | 1,764 |
| Ratio of Total Citations to Distinct Citing Papers | 1.19 | 1.21 |
| Self-Citation Percentage |
5.81%
|
|
Linette, Gerald P.
University of Pennsylvania Perelman School of Medicine,
United States
2024 Rank: 98,493
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 3,241 out of 334,837 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 98,493 | 110,896 |
| Total Cites | 2,187 | 2,301 |
| H-index | 19 | 20 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 16 | 16 |
| Total Cites to Single+First Authored Papers | 111 | 111 |
| Number of Single+First+Last Authored Papers | 23 | 23 |
| Total Cites to Single+First+Last Authored Papers | 210 | 211 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 1,800 | 1,875 |
| Ratio of Total Citations to Distinct Citing Papers | 1.22 | 1.23 |
| Self-Citation Percentage |
4.95%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 3,499 out of 312,644 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 98,033 | 113,082 |
| Total Cites | 2,421 | 2,559 |
| H-index | 20 | 20 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 16 | 16 |
| Total Cites to Single+First Authored Papers | 110 | 111 |
| Number of Single+First+Last Authored Papers | 23 | 23 |
| Total Cites to Single+First+Last Authored Papers | 242 | 246 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 1,924 | 2,009 |
| Ratio of Total Citations to Distinct Citing Papers | 1.26 | 1.27 |
| Self-Citation Percentage |
5.39%
|
|
Linette, Gerald P.
University of Pennsylvania Perelman School of Medicine,
United States
2022 Rank: 87,245
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 3,315 out of 293,195 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 87,245 | 98,046 |
| Total Cites | 2,754 | 2,905 |
| H-index | 19 | 19 |
| Hm-index | 3 | 4 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 15 | 15 |
| Total Cites to Single+First Authored Papers | 113 | 115 |
| Number of Single+First+Last Authored Papers | 22 | 22 |
| Total Cites to Single+First+Last Authored Papers | 268 | 280 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 2,229 | 2,324 |
| Ratio of Total Citations to Distinct Citing Papers | 1.24 | 1.25 |
| Self-Citation Percentage |
5.20%
|
|
Linette, Gerald P.
University of Pennsylvania Perelman School of Medicine,
United States
2021 Rank: 91,052
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 3,279 out of 271,773 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 91,052 | 102,194 |
| Total Cites | 4,386 | 4,646 |
| H-index | 21 | 22 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 15 | 15 |
| Total Cites to Single+First Authored Papers | 174 | 179 |
| Number of Single+First+Last Authored Papers | 22 | 22 |
| Total Cites to Single+First+Last Authored Papers | 395 | 410 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 3,428 | 3,571 |
| Ratio of Total Citations to Distinct Citing Papers | 1.28 | 1.30 |
| Self-Citation Percentage |
5.60%
|
|
Linette, Gerald P.
University of Pennsylvania Perelman School of Medicine,
United States
2020 Rank: 83,682
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 2,922 out of 230,678 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 83,682 | 95,758 |
| Total Cites | 3,558 | 3,803 |
| H-index | 19 | 19 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 15 | 15 |
| Total Cites to Single+First Authored Papers | 134 | 141 |
| Number of Single+First+Last Authored Papers | 22 | 22 |
| Total Cites to Single+First+Last Authored Papers | 321 | 335 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 2,654 | 2,779 |
| Ratio of Total Citations to Distinct Citing Papers | 1.34 | 1.37 |
| Self-Citation Percentage |
6.44%
|
|
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.